Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

BACKGROUND: For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years inste...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Christina, Pan, Hongchao, Godwin, Jon, Gray, Richard, Arriagada, Rodrigo, Raina, Vinod, Abraham, Mirta, Alencar, Victor Hugo Medeiros, Badran, Atef, Bonfill, Xavier, Bradbury, Joan, Clarke, Michael, Collins, Rory, Davis, Susan R, Delmestri, Antonella, Forbes, John F, Haddad, Peiman, Hou, Ming-Feng, Inbar, Moshe, Khaled, Hussein, Kielanowska, Joanna, Kwan, Wing-Hong, Mathew, Beela S, Müller, Bettina, Nicolucci, Antonio, Peralta, Octavio, Pernas, Fany, Petruzelka, Lubos, Pienkowski, Tadeusz, Rajan, Balakrishnan, Rubach, Maryna T, Tort, Sera, Urrútia, Gerard, Valentini, Miriam, Wang, Yaochen, Peto, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/
https://www.ncbi.nlm.nih.gov/pubmed/23219286
http://dx.doi.org/10.1016/S0140-6736(12)61963-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/
https://www.ncbi.nlm.nih.gov/pubmed/23219286
http://dx.doi.org/10.1016/S0140-6736(12)61963-1

Ejemplares similares